WO2026041784 - OLIGONUCLEOTIDES FOR MODULATING SYNAPTOGYRIN-3 EXPRESSION
National phase entry is expected:
Publication Number
WO/2026/041784
Publication Date
26.02.2026
International Application No.
PCT/EP2025/074001
International Filing Date
22.08.2025
Title **
[English]
OLIGONUCLEOTIDES FOR MODULATING SYNAPTOGYRIN-3 EXPRESSION
[French]
OLIGONUCLÉOTIDES POUR MODULER L'EXPRESSION DE LA SYNAPTOGYRINE-3
Applicants **
VIB VZW
KATHOLIEKE UNIVERSITEIT LEUVEN
JAY THERAPEUTICS
Inventors
VERSTREKEN, Patrik
SANTOS, Ana Rita
Priority Data
24196251.3
23.08.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2404 | |
| EPO | Filing, Examination, Granting | 12110 | |
| Japan | Filing, Examination, Granting | 2362 | |
| South Korea | Filing, Examination, Granting | 2422 | |
| USA | Filing, Examination, Granting | 4940 |
Total:
24,238
Contact Us
Abstract[English]
The invention relates to an oligonucleotide comprising a gapmer of formula 5'-F-G-F'-3', where each one of F and F' is a region which independently comprises between 3 and 4 nucleosides, and wherein each one of said F and F' region independently comprises at least one chemically modified nucleoside defining the 5' and 3' end of the F and F' region, and wherein G is a region between 9 and 11 nucleosides for recruiting RNaseH, which oligonucleotide can target regions within the synaptogyrin-3 RNA sequence. In particular, these oligonucleotides are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.[French]
L'invention concerne un oligonucléotide comprenant un gapmer de formule 5'-F-G-F'-3', chacun de F et de F' étant une région qui comprend indépendamment entre 3 et 4 nucléosides, et chacune desdites régions F et F' comprenant indépendamment au moins un nucléoside chimiquement modifié définissant l'extrémité 5' et 3' de la région F et F', et G étant une région comprenant entre 9 et 11 nucléosides pour recruter la RNaseH, ledit oligonucléotide pouvant cibler des régions à l'intérieur de la séquence d'ARN de la synaptogyrine-3. En particulier, ces oligonucléotides sont destinés à être utilisés en tant que médicament en général, et pour traiter ou inhiber la progression de tauopathies ou de symptômes de tauopathies.